HCPCS
J0896
0.25 mg = 1 unit
Phase 1
Identify what you're billing
Confirm indication, dose ceiling, and the 0.25 mg unit basis before billing.
Mechanism & class — first-in-class erythroid maturation agent FDA verified May 2026
Reblozyl is a TGF-β superfamily ligand trap. It is NOT an ESA.
Reblozyl (luspatercept-aamt) is a recombinant fusion protein consisting of a modified human activin receptor type IIB extracellular domain linked to the human IgG1 Fc domain. It binds and sequesters select TGF-β superfamily ligands (including GDF11), reducing aberrant Smad2/3 signaling and allowing terminal differentiation of late-stage erythroid precursors. The result is improved RBC production in patients with ineffective erythropoiesis — without driving early erythroid expansion the way an EPO-receptor agonist does.
Why class matters for billing. Reblozyl is the first and only approved erythroid maturation
agent. It does NOT compete with or substitute for ESAs in the same patient at the same time, and it does
NOT treat iron-deficiency anemia. Match the indication and the diagnosis — payers will deny if the
ICD-10 implies pure iron deficiency or non-MDS / non-thalassemia anemia.
Dosing by indication FDA label verified May 2026
All three indications start at 1 mg/kg SC q3wk. Titration ceilings differ.
| Indication | Starting dose | Max titrated dose | FDA approval |
|---|---|---|---|
| Beta-thalassemia (transfusion-dependent) | 1 mg/kg SC q3wk | 1.25 mg/kg SC q3wk | Nov 2019 |
| MDS-RS / MDS-MPN-RS-T (post-ESA) | 1 mg/kg SC q3wk | 1.75 mg/kg SC q3wk | Apr 2020 |
| Lower-risk MDS, 1L (COMMANDS) | 1 mg/kg SC q3wk | 1.75 mg/kg SC q3wk | Aug 2023 |
Titration rules (per FDA label)
- Reassess after each 3-dose interval. Titrate up if inadequate transfusion reduction (per indication-specific RBC criteria).
- Hold if Hgb > 11.5 g/dL prior to a dose; resume at one dose level lower when Hgb falls below threshold.
- Discontinue if no transfusion reduction after 9 weeks (3 doses) at the maximum titrated dose.
- Continue while clinical benefit persists; no fixed treatment duration.
Vial selection & dose preparation
- 25 mg single-dose vial (NDC 59572-705-01) reconstituted to 25 mg/0.5 mL (50 mg/mL).
- 75 mg single-dose vial (NDC 59572-707-01) reconstituted to 75 mg/1.5 mL (50 mg/mL).
- Round dose to nearest whole-vial increment per FDA label dose-preparation table; partial-vial waste is common — bill JW for discarded units.
Unit math — the 0.25 mg trap CMS HCPCS verified May 2026
Always divide administered mg by 0.25 to get billable units.
Worked example — 70 kg lower-risk MDS patient (1 mg/kg)
# Compute administered mg from weight-based dose
Patient weight: 70 kg
Dose: 1 mg/kg SC q3wk
Administered: 70 mg
# Convert mg to J0896 units (1 unit = 0.25 mg)
Units billed: 70 / 0.25 = 280 units (J0896)
# Vial selection & waste
Vial: 1 × 75 mg single-dose vial (NDC 59572-707-01)
Drug discarded: 5 mg = 20 units (JW)
# Reimbursement at Q2 2026 ASP+6% ($42.75/unit)
Drug paid (admin): 280 × $42.75 = $11,970.00 (JZ)
Drug paid (waste): 20 × $42.75 = $855.00 (JW)
Total drug paid: $12,825.00 per dose
Patient weight: 70 kg
Dose: 1 mg/kg SC q3wk
Administered: 70 mg
# Convert mg to J0896 units (1 unit = 0.25 mg)
Units billed: 70 / 0.25 = 280 units (J0896)
# Vial selection & waste
Vial: 1 × 75 mg single-dose vial (NDC 59572-707-01)
Drug discarded: 5 mg = 20 units (JW)
# Reimbursement at Q2 2026 ASP+6% ($42.75/unit)
Drug paid (admin): 280 × $42.75 = $11,970.00 (JZ)
Drug paid (waste): 20 × $42.75 = $855.00 (JW)
Total drug paid: $12,825.00 per dose
Common dose → unit conversion table (70 kg patient)
| Dose | mg administered | Units (J0896) | Vial(s) used | Waste mg / units (JW) |
|---|---|---|---|---|
| 1.0 mg/kg start | 70 mg | 280 | 1 × 75 mg | 5 mg / 20 units |
| 1.25 mg/kg (beta-thal max) | 87.5 mg | 350 | 1 × 75 mg + 1 × 25 mg | 12.5 mg / 50 units |
| 1.5 mg/kg (MDS interim) | 105 mg | 420 | 1 × 75 mg + 2 × 25 mg | 20 mg / 80 units |
| 1.75 mg/kg (MDS max) | 122.5 mg | 490 | 1 × 75 mg + 2 × 25 mg | 2.5 mg / 10 units |
Underbilling alert. Coding J0896 at 1 mg per unit (treating it like Aranesp's 1 mcg unit
or a typical 1 mg-per-unit J-code) underpays by 4×. A 70 mg dose billed as 70 units instead of 280
units shorts the practice by ~$8,977 per dose at Q2 2026 ASP+6%.
NDC reference FDA NDC Directory verified May 2026
| NDC (10/11-digit) | Vial | Reconstituted concentration | Use |
|---|---|---|---|
59572-705-01 / 59572-0705-01 |
25 mg single-dose lyophilized vial | 25 mg / 0.5 mL (50 mg/mL) | Smaller patients, fine-titration top-up |
59572-707-01 / 59572-0707-01 |
75 mg single-dose lyophilized vial | 75 mg / 1.5 mL (50 mg/mL) | Most adult doses; pair with 25 mg vial for higher titrations |
Use the N4 + 11-digit NDC format on the claim form. Box 24A shaded area:
N4 59572070501 for the 25 mg vial or N4 59572070701 for the 75 mg vial, with
ML qualifier and total reconstituted volume. Vial-level NDC is the correct level for J0896 (no carton
ambiguity — vials ship as single-vial cartons).
Phase 2
Code the claim
SC therapeutic admin (96372) — not IV, not chemo. Modifier discipline matters.
Administration codes CPT verified May 2026
Reblozyl is a subcutaneous therapeutic injection. Bill 96372 by default.
| Code | Description | When to use |
|---|---|---|
96372 |
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | Primary code for Reblozyl. SC injection in upper arm, thigh, or abdomen. |
96401 |
Chemotherapy administration, SC/IM; non-hormonal anti-neoplastic | Some payers prefer 96401 for biologic disease-modifying agents in oncology / heme settings. Verify per payer. Aetna and some commercial plans accept either. |
96365 / 96413 |
Therapeutic IV / chemotherapy IV | NOT appropriate. Reblozyl is SC only. Billing IV admin codes will trigger denial. |
96379 |
Unlisted therapeutic / diagnostic injection | Avoid — 96372 covers subcutaneous administration explicitly. |
96372 vs 96401 — payer split. Most major payers accept 96372 (therapeutic SC) for
Reblozyl. A minority of oncology/hematology departments default to 96401 (chemo SC) for biologics.
Reblozyl is not classically a chemotherapeutic, but it is administered in heme/onc clinics for MDS —
verify the preferred code with each contracted payer before initiating therapy.
Modifiers CMS verified May 2026
JZ — no waste discarded
Effective July 1, 2023, CMS requires JZ on all single-dose container claims when no drug is discarded. Reblozyl ships in 25 mg and 75 mg single-dose vials. JZ is appropriate when the dose lines up cleanly with vial size (e.g., a patient whose calculated dose hits 75 mg or 100 mg exactly).
JW — discarded portion
JW is the more common modifier on Reblozyl claims. Weight-based dosing (1–1.75 mg/kg) almost never produces an exact 25 mg or 75 mg total, so partial-vial waste is the norm. Bill the administered units on the JZ-style admin line and the discarded units on a separate JW line. One of JZ or JW must be on every J0896 claim.
Example. 70 kg patient, 1 mg/kg = 70 mg administered = 280 units (admin line). One 75 mg
vial used; 5 mg discarded = 20 units (JW line). Both lines must reflect the 0.25 mg unit basis.
Modifier 25 — same-day E/M
Use modifier 25 on the E/M code when a significant, separately identifiable evaluation and management service is performed on the same day as the injection (common at titration visits where labs are reviewed and dose adjusted).
340B modifiers (JG, TB)
For 340B-acquired Reblozyl, follow your MAC's current 340B modifier policy. BMS Access Support does not provide 340B-specific instructions; Reblozyl is commonly carved out of 340B in heme/onc clinics due to site-of-care policies, but practice patterns vary.
ICD-10-CM by indication FY2026 verified May 2026
Use the most specific code supported by hematologic and transfusion-history documentation.
| Indication | ICD-10 family | Notes |
|---|---|---|
| Beta-thalassemia (primary) | D56.1 | Beta thalassemia — the labeled population |
| Other thalassemia (rule-in/rule-out) | D56.0, D56.2, D56.3, D56.4, D56.5, D56.8, D56.9 | D56.1 specifically required for the FDA-labeled beta-thalassemia indication |
| Sickle cell variants (often co-coded) | D57.0–D57.4 | Co-coded but not the primary Reblozyl indication |
| MDS unspecified | D46.9 | Generic MDS — payers will require IPSS-R risk and ring-sideroblast status documentation |
| MDS, refractory anemia, no sideroblasts | D46.0 | Eligible for 1L COMMANDS indication |
| MDS-RS (refractory anemia w/ ring sideroblasts) | D46.1 | Original 2020 indication post-ESA |
| MDS w/ excess blasts | D46.20, D46.21, D46.22, D46.A | Lower-risk subset only (IPSS-R very-low/low/intermediate); higher-risk MDS not labeled |
| MDS, refractory anemia unspecified | D46.4 | Lower-risk subset only |
| MDS/MPN-RS-T | D47.3 or D46.9 + clinical documentation | Specific subset eligible alongside MDS-RS |
| Long-term transfusion dependence | Z79.890 + Z51.81 | Co-code with transfusion history (encounter-specific) |
| Anemia, unspecified | D64.9 | Avoid as primary. Will trigger denial; payers want the specific underlying diagnosis |
IPSS-R risk and ring-sideroblast status are typically PA requirements for MDS indications.
UnitedHealthcare and Aetna require documentation that the patient is IPSS-R very-low, low, or
intermediate-risk for the 1L COMMANDS indication, and ring-sideroblast confirmation (≥ 15% of erythroid
precursors, or ≥ 5% with SF3B1 mutation) for the MDS-RS post-ESA pathway. Submit bone marrow biopsy
results with the PA.
Site of care & place of service Verified May 2026
Reblozyl is a subcutaneous injection administered in heme/onc clinic, ambulatory infusion center, or physician office. The 1–2 minute SC injection makes office (POS 11) and ambulatory infusion suite (POS 49) the standard sites; HOPD is uncommon and increasingly disfavored by commercial UM.
| Setting | POS | Claim form | Payer steering |
|---|---|---|---|
| Hematology/oncology office | 11 | CMS-1500 / 837P | Preferred by commercial UM |
| Ambulatory infusion suite (AIC) | 49 | CMS-1500 / 837P | Preferred by commercial UM |
| Hospital outpatient (on-campus) | 22 | UB-04 / 837I | Disfavored — SC injection does not require HOPD |
| Hospital outpatient (off-campus PBD) | 19 | UB-04 / 837I | Disfavored |
| Patient home | 12 | CMS-1500 (with home-infusion vendor) | Possible — SC route supports home administration if logistically feasible |
Site-of-care opportunity: Because Reblozyl is SC and given q3wk, home administration via a
certified home-infusion / home-injection vendor is plausible for stable patients on a settled dose —
but verify payer coverage. Most commercial plans accept office or AIC; home is plan-specific.
Claim form field mapping BMS Access Support Mar 2026
Standard CMS-1500 / 837P billing for outpatient SC injection.
| Information | CMS-1500 box | Notes |
|---|---|---|
| NPI | 17b | Rendering provider (heme/onc specialist) |
| NDC qualifier + 11-digit NDC + UoM + qty | 24A shaded area | N4 + vial NDC + ML + reconstituted volume (0.5 mL for 25 mg vial; 1.5 mL for 75 mg vial) |
| HCPCS J0896 + JZ (administered units) | 24D (drug line) | Units = mg administered ÷ 0.25 |
| HCPCS J0896 + JW (discarded units) | 24D (separate line) | Required when partial-vial waste occurs (most claims) |
| Drug units | 24G | 0.25 mg unit basis — double-check on every claim |
| CPT 96372 (admin line) | 24D (admin line) | SC therapeutic injection (or 96401 if payer prefers) |
| ICD-10 | 21 | Indication-specific (D56.1 / D46.x / D47.3) plus transfusion-dependence codes |
| PA number | 23 | Required by virtually every commercial payer |
Phase 3
Get paid
MDS landscape, payer policies, and Medicare reimbursement.
Anemia treatment landscape — where Reblozyl fits NCCN MDS verified May 2026
Three classes, three mechanisms, three patient populations.
| Class | Drug examples | Mechanism | Primary patient |
|---|---|---|---|
| Erythroid maturation agent | Reblozyl (J0896, luspatercept-aamt) | TGF-β ligand trap — late-stage erythroid maturation | Beta-thalassemia transfusion-dependent; lower-risk MDS (1L per COMMANDS or post-ESA MDS-RS) |
| Erythropoiesis-stimulating agents (ESAs) | Aranesp (J0881/J0882, darbepoetin); Epogen / Procrit (J0885, epoetin alfa); Mircera (J0887/J0888) | EPO-receptor agonist — early erythropoiesis stimulation | CKD anemia, chemotherapy-induced anemia, lower-risk MDS (historically 1L; COMMANDS shifted preference) |
| IV iron replacement | Injectafer (J1439, ferric carboxymaltose); Feraheme (Q0138/Q0139 historic, J1439, ferumoxytol); Monoferric (J1437, ferric derisomaltose) | Repletes iron stores — corrects iron-deficiency anemia | Iron-deficiency anemia (heavy menstrual bleeding, GI loss, post-bariatric, CKD-associated IDA) |
The COMMANDS shift (2023–2024)
Prior to August 2023, lower-risk MDS first-line therapy for transfusion-dependent anemia was an ESA (epoetin alfa or darbepoetin). Reblozyl was reserved for MDS-RS patients who had already failed an ESA. The COMMANDS phase 3 trial (published NEJM 2024) showed luspatercept achieved superior RBC transfusion independence vs. epoetin alfa in 1L lower-risk MDS — including in non-RS patients. The FDA label was expanded August 28, 2023 to permit 1L use in lower-risk MDS regardless of prior ESA exposure. NCCN MDS guidelines now list luspatercept and epoetin alfa as parallel 1L options, with luspatercept preferred for patients with serum EPO > 200 mU/mL or expected lower ESA response.
Billing implication. Practices should expect more J0896 claims and fewer J0881/J0882
(Aranesp) or J0885 (Epogen) claims in lower-risk MDS over 2024–2026. PA criteria for the COMMANDS
indication require IPSS-R documentation but do NOT require prior ESA failure.
Payer policy snapshot Reviewed May 2026
All major payers require PA. MDS PAs require IPSS-R + ring-sideroblast / blast status.
| Payer | PA? | Key clinical criteria | Step / preference notes |
|---|---|---|---|
| UnitedHealthcare Medical Drug Coverage Policy |
Yes | Beta-thalassemia: D56.1 + transfusion-dependence documentation. MDS post-ESA: ESA failure history + MDS-RS confirmation. MDS 1L COMMANDS: IPSS-R very-low/low/intermediate + transfusion dependence. | Specialist (heme/onc) prescription required; site-of-care UM does NOT typically apply (SC injection) |
| Aetna CPB + Medical Drug policies |
Yes | Same as UHC; bone marrow biopsy results required for MDS PAs; Hgb < 11.5 g/dL prior to dose | Aligned with FDA label; no step therapy through ESA for the COMMANDS 1L indication |
| BCBS plans Vary by plan |
Yes | Generally aligned with NCCN MDS Guidelines + FDA label; many plans still require ESA trial as step therapy in MDS even after COMMANDS — appeal with NCCN evidence | Verify per plan; serum EPO documentation often requested |
| Medicare (MAC LCDs) | No PA at original Medicare | Coverage per FDA label; no NCD specific to luspatercept | MA plans may impose PA per their formulary |
Step therapy
For the original beta-thalassemia and MDS-RS post-ESA indications, step therapy is largely by FDA-label sequence (transfusion dependence; ESA failure for MDS-RS). For the August 2023 COMMANDS 1L MDS expansion, FDA does NOT require prior ESA failure — but some commercial plans still impose ESA step therapy as of mid-2026. Appeal with NCCN MDS Guidelines and the COMMANDS NEJM 2024 publication.
Medicare reimbursement CMS Q2 2026 (live)
Quarterly ASP from CMS Part B Drug Pricing File. Refreshes automatically each quarter.
Q2 2026 payment snapshot — J0896
Effective April 1 – June 30, 2026 · Based on 4Q25 ASP submissions
ASP + 6% per unit
$42.750
per 0.25 mg unit
70 mg dose (1 mg/kg, 70 kg)
$11,970.00
280 units × ASP+6%
122.5 mg dose (1.75 mg/kg, 70 kg)
$20,947.50
490 units × ASP+6%
Annualized cost (70 kg patient, 1 mg/kg q3wk, ~17 doses/year):
70 mg × $171.000/mg × 17 doses ≈
$203,490/year drug cost at Q2 2026 ASP+6% (before sequestration). At max titrated
1.75 mg/kg, ~$356,108/year. After ~2% sequestration: ~$199,400 (1 mg/kg) or ~$348,900 (1.75 mg/kg) actual paid.
Coverage
No NCD specific to luspatercept-aamt. Coverage falls under MAC LCDs for biologics and the generic drug-coverage framework. All MACs cover J0896 for FDA-approved on-label indications with appropriate ICD-10, transfusion-dependence documentation, and (for MDS) IPSS-R and ring-sideroblast status.
Code history
- J0896 — permanent code, "Inj luspatercept-aamt 0.25 mg"
- Pre-permanent-code period after Nov 2019 launch used unclassified
J3490/J3590with NDC documentation - Q2 2026 ASP+6% reflects 4Q25 submissions and applies April 1 – June 30, 2026
Patient assistance — BMS Access Support & Reblozyl Patient Support BMS verified May 2026
- BMS Access Support: 1-800-861-0048 / bmsaccesssupport.com — benefits investigation, prior authorization assistance, appeal support
- Reblozyl Patient Support: 1-888-732-7568 (Reblozyl-specific intake)
- Reblozyl Co-Pay Assistance Program: commercial copay support; $0 first dose for eligible commercially-insured patients (excludes Medicare, Medicaid, federal program patients)
- BMS Patient Assistance Foundation: free product for uninsured / underinsured patients meeting income requirements (501(c)(3) administered through BMS Patient Assistance Program, Inc.)
- Foundations (Medicare patients): PAN Foundation, HealthWell, CancerCare — verify open MDS/anemia/beta-thalassemia funds quarterly
- Web: bmsaccesssupport.com
Need to model what a specific patient will actually pay after copay assistance, deductible, coinsurance,
and OOP max? Run a CareCost Estimate — J0896 pre-loaded with the
0.25 mg unit basis already wired in.
Phase 4
Safety & problems
No boxed warning, but two indication-specific safety signals worth flagging in PA letters.
Thromboembolic events — especially in beta-thalassemia FDA W&P
Thromboembolic events were reported in 8/223 (3.6%) beta-thalassemia patients in the BELIEVE trial
— including DVT, PE, portal vein thrombosis, and ischemic stroke. Risk is higher in beta-thalassemia
patients with prior splenectomy, history of thromboembolism, or known thrombophilia.
Risk-mitigation documentation
- Document baseline thromboembolic history; weigh benefit/risk for splenectomized beta-thalassemia patients
- Concomitant prophylactic anticoagulation should be considered per institutional protocol for high-risk beta-thalassemia patients
- Educate patients on signs/symptoms of DVT, PE, stroke; instruct immediate reporting
- MDS patients had thromboembolic events at lower rates in MEDALIST and COMMANDS, but still document baseline risk
Extramedullary hematopoietic masses (EMH) — beta-thalassemia FDA W&P
EMH masses were reported in beta-thalassemia patients in BELIEVE and BEYOND clinical trials.
These masses can compress neural structures (spinal cord) and cause serious neurologic complications. Risk
is higher in patients with prior history of EMH masses or splenectomy.
Surveillance & documentation
- Baseline assessment for prior EMH history in beta-thalassemia patients
- Monitor for symptoms suggesting mass effect (back pain, neurologic deficits, neuropathic symptoms) at every visit
- Prompt imaging if symptoms develop; discontinue if EMH masses identified
- EMH not reported as a significant signal in the MDS indications; primarily a beta-thalassemia concern
Common denials & how to fix them
| Denial reason | Common cause | Fix |
|---|---|---|
| Units appear too low / drug cost mismatch | Billed at 1 mg per unit instead of 0.25 mg per unit | Resubmit with units = mg administered ÷ 0.25. The single most common Reblozyl error. |
| Units appear too high (4× expected) | Billed mg directly without dividing by 0.25 (rare reverse error) | Verify J0896 descriptor: "Inj luspatercept-aamt 0.25 mg" — double-check unit math. |
| Wrong admin code (96365 IV) | IV admin billed for SC drug | Resubmit with 96372 (SC therapeutic) or 96401 if payer-preferred. |
| JW missing on weight-based dose | Wasted drug not reported — partial-vial waste is the norm | Add JW line for discarded units. JZ on administered units; JW on wasted units. |
| JZ missing on adult claim with no waste | Single-dose vial claim without modifier | Required since 7/1/2023 on every claim with no waste. |
| ESA step therapy required (commercial plans) | 1L COMMANDS indication denied for lack of prior ESA failure | Appeal citing FDA label expansion (Aug 2023), COMMANDS NEJM 2024 publication, and NCCN MDS Guidelines listing luspatercept and ESA as parallel 1L options. |
| MDS PA missing IPSS-R or ring-sideroblast status | Bone marrow biopsy results not submitted with PA | Submit complete BMA with cytogenetics, blast %, ring-sideroblast %, IPSS-R calculation, and SF3B1 mutation status if available. |
| Beta-thalassemia PA without transfusion documentation | D56.1 alone without transfusion history | Submit transfusion log: dates, units, indication. Beta-thalassemia indication requires "regular RBC transfusions" per FDA label. |
| Wrong NDC (vial vs carton confusion) | Reblozyl ships single-vial cartons; NDC confusion is rare but happens | Use vial-level NDC: 59572-705-01 (25 mg) or 59572-707-01 (75 mg) with 11-digit format. |
| Indication outside FDA label | D64.9 (anemia unspecified) or higher-risk MDS billed | FDA label is specific: beta-thalassemia, MDS-RS post-ESA, lower-risk MDS 1L. Higher-risk MDS not covered. |
Frequently asked questions
What is the HCPCS code for Reblozyl?
Reblozyl (luspatercept-aamt) is billed under HCPCS J0896 — "Injection,
luspatercept-aamt, 0.25 mg." One billable unit equals 0.25 mg, NOT 1 mg. This unusual unit
basis is the single most common biller error: a 70 kg patient receiving 1 mg/kg (70 mg) is billed as
280 units (70 ÷ 0.25), not 70 units.
How many units do I bill for a 70 mg Reblozyl dose?
Bill 280 units of J0896 for a 70 mg dose (70 ÷ 0.25 = 280). Always
divide the administered milligrams by 0.25 to get billable units. Common doses: 1 mg/kg in a 70 kg patient
= 70 mg = 280 units; 1.25 mg/kg in 70 kg = 87.5 mg = 350 units; 1.75 mg/kg in 70 kg = 122.5 mg = 490 units.
What administration CPT do I use for Reblozyl?
CPT 96372 — "Therapeutic, prophylactic, or diagnostic injection (specify substance or
drug); subcutaneous or intramuscular." Reblozyl is a SC injection (upper arm, thigh, or abdomen).
Do NOT bill 96365 (therapeutic IV) — Reblozyl is not an IV drug. Some heme/onc payers
prefer 96401 (chemotherapy SC, non-hormonal anti-neoplastic) for the biologic — verify
with each payer.
Do I bill JZ or JW for Reblozyl?
Both are likely on Reblozyl claims. Reblozyl ships in fixed 25 mg and 75 mg single-dose vials, but doses are weight-based (1 to 1.75 mg/kg), so partial-vial waste is common. Bill JZ on the administered units when no waste occurs (rare); bill JW on the discarded units when waste occurs. Example: a 70 kg patient receiving 70 mg uses one 75 mg vial — bill 280 units administered (JZ) and 20 units (5 mg waste) on a separate JW line.
What is the Medicare reimbursement for J0896?
For Q2 2026, the Medicare Part B payment limit for J0896 is $42.750 per unit (0.25 mg) — equivalently $171.000 per mg (ASP + 6%). A 70 mg dose (1 mg/kg, 70 kg patient) reimburses at approximately $11,970.00; a 122.5 mg dose (1.75 mg/kg, 70 kg patient) reimburses at approximately $20,947.50. Sequestration (~2%) reduces actual paid to roughly ASP + 4.3%.
What are Reblozyl's approved indications?
Three FDA-approved indications: (1) anemia in adult beta-thalassemia patients who require regular RBC transfusions (Nov 2019); (2) anemia in adult MDS-RS or MDS/MPN-RS-T after ESA failure (Apr 2020); (3) anemia in adult lower-risk MDS (IPSS-R very-low/low/intermediate) who may require RBC transfusions, FIRST-LINE — no prior ESA required (Aug 2023, COMMANDS trial expansion). The 2023 1L MDS expansion is the major billing addition that puts Reblozyl in direct competition with ESAs (Aranesp J0881/J0882, Epogen J0885).
What dose do I use for which indication?
All three indications start at 1 mg/kg SC every 3 weeks. Titration ceilings differ: beta-thalassemia max is 1.25 mg/kg; MDS (both post-ESA and 1L) max is 1.75 mg/kg. Discontinue if no transfusion reduction after 9 weeks (3 doses) at the maximum titrated dose. Round dose to the nearest whole-vial increment per FDA label dose preparation instructions.
How is Reblozyl different from ESAs like Aranesp or Epogen?
Different mechanism, different patient. Reblozyl is a TGF-β superfamily ligand trap — it acts on late-stage erythroid maturation, allowing terminal differentiation of erythroid precursors. ESAs (epoetin alfa Epogen J0885, darbepoetin Aranesp J0881/J0882) act early by stimulating erythropoiesis via the EPO receptor. Reblozyl was first approved in lower-risk MDS only after ESA failure (2020), but the COMMANDS trial showed superior transfusion-independence vs. epoetin alfa in 1L lower-risk MDS, leading to the August 2023 1L expansion. Reblozyl does NOT replace IV iron (Injectafer, Feraheme, Monoferric) — those treat iron-deficiency anemia, a different patient entirely.
Reference
Sources & methodology
Every claim on this page is sourced. Methodology and review history below.
Source documents
- BMS Access Support — Reblozyl Coding & Coverage HCP page
- DailyMed — REBLOZYL (luspatercept-aamt) Prescribing Information
- FDA — Luspatercept-aamt approval letters (2019, 2020, 2023)
- COMMANDS Trial — Luspatercept vs. Epoetin Alfa in 1L Lower-Risk MDS (NEJM 2024)
- CMS — Medicare Part B Drug ASP Pricing File
- SEER CanMED — HCPCS J0896 reference
- UnitedHealthcare — Medical Drug Coverage Policies (luspatercept)
- Aetna — Clinical Policy Bulletins (luspatercept-aamt)
- NCCN MDS Guidelines — Luspatercept and Epoetin alfa as parallel 1L options for lower-risk MDS
- FDA National Drug Code Directory
About this page
We maintain this page as a living reference. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.
Found an error? Email hello@carecostestimate.com.
Refresh cadence
| Element | Cadence | How it's refreshed |
|---|---|---|
| Medicare ASP pricing | Quarterly | Auto-bound to CareCost ASP layer; updates on CMS file release. |
| Payer policies (UHC, Aetna, BCBS) | Semi-annual | Manual review against published payer policy documents. |
| HCPCS / CPT / modifier rules | Annual | Reviewed against CMS HCPCS quarterly files and AMA CPT releases. |
| NDC, dosing, FDA label, indication list | Event-driven | Tied to manufacturer document version + FDA label revision date. |
Reviewer
Pending SME review. This page is staff-authored from primary sources (FDA, CMS,
manufacturer, payer documents — all linked above). Editorial review in progress. Until that review is complete, treat this as a draft reference and verify each cited
source for high-stakes claims.
Change log
- — Initial publication. ASP data: Q2 2026. Manufacturer source: BMS Access Support Mar 2026. FDA label revision reflects Aug 2023 COMMANDS 1L MDS expansion. 0.25 mg unit basis flagged as primary biller-error trap.
Methodology
Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File. Payer policies are read directly from each payer's published medical/pharmacy policy documents. Indication list is verified against the current FDA label revision and FDA approval letters. We do not paraphrase from billing-software vendor blogs.